Functional Constipation in Children Ages 6-17 YearsPhase 2NCT02559570
A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)
A Phase 2 study testing LIN Dose A, LIN Dose B and LIN Dose C in people with Functional Constipation in Children Ages 6-17 Years, run by Forest Laboratories at 62 sites in 2 countries.
Trial summary
The purpose of this study was to evaluate dose response of the safety and efficacy of linaclotide for the treatment of functional constipation (FC), in children age 6-17 years. This study includes up to a 4-week Screening Period, and a 2 to 3-week Pretreatment Period. Read more about this study
- Who is it for?
- Ages 6 to 17 years
- Conditions the study is for
- Functional Constipation in Children Ages 6-17 Years
- What is being tested?
- LIN Dose A, LIN Dose B and LIN Dose C
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 173 participants
- Where
- 62 sitesin 2 countries
- Study dates
- 3 Nov 2015to 29 May 2018
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Participant weighs at least 18 kg (kilograms) (39.7 lbs)
- Participant meets modified Rome III criteria for child/adolescent FC: For at least 2 months before the Screening Visit, the participant has had 2 or fewer defecations (with each defecation occurring in the absence of any laxative, suppository, or enema use during the preceding 24 hours) in the toilet per week. In addition, at least once per week, patient meets 1 or more of the following:
- a) History of retentive posturing or excessive volitional stool retention
- b) History of painful or hard bowel movements (BMs)
- c) Presence of a large faecal mass in the rectum
- d) History of large diameter stools that may obstruct the toilet
Show all 10Show fewer
- e) At least one episode of fecal incontinence per week
- Participant is willing to discontinue any laxatives used before the Pretreatment Visit in favor of the protocol-permitted rescue medicine
- Participant has an average of fewer than 3 spontaneous BMs (SBMs) per week during the 14 days before the randomization day and up to the randomization. An SBM is defined as a BM that occurs in the absence of laxative, enema, or suppository use on the calendar day of the BM or the calendar day before the BM
- Participant or participant/guardian/legally authorized representative (LAR) or caregiver is compliant with electronic diary (eDiary) by completing both the morning and evening assessments for 10 out of the 14 days immediately preceding the Randomization Visit
Who cannot join
- Participant meets Rome III criteria for Child/Adolescent irritable bowel syndrome (IBS): At least once per week for at least 2 months before the Screening Visit, the participant has experienced abdominal discomfort (an uncomfortable sensation not described as pain) or pain associated with 2 or more of the following at least 25% of the time:
- 1. Improvement with defecation
- 2. Onset associated with a change in frequency of stool
- 3. Onset associated with a change in form (appearance) of stool
- Participant reports having more than 1 loose, mushy stool (eDiary-recorded stool consistency of 6 on the Pediatric Bristol Stool Form Scale [p-BSFS]) or any watery stool (eDiary-recorded stool consistency of 7 on the p-BSFS) with any SBM that occurred in the absence of laxative use on the calendar day of the BM or the calendar day before the BM during the 14 days before the randomization day and up to the randomization
- Select medical history or conditions that may be related to other causes of constipation or may interfere with safety and efficacy analyses
- Participant has required manual or hospital-based disimpassion any time prior to randomization
- Participant is unable to tolerate the placebo during the Screening Period
Trial locations and contacts
62 sites in 2 countries.
62 sites in 2 countries
United States60 sites
Advanced Research Center
Anaheim, California, 92805
Asheboro Research Associates
Asheboro, North Carolina, 27203
Children's Center for Digestive Health Care LLC
Atlanta, Georgia, 30342
University of Maryland Children's Hospital
Baltimore, Maryland, 21201
Kentucky Pediatric/ Adult Research
Bardstown, Kentucky, 40004
Massachusetts General Hospital
Boston, Massachusetts, 02114
Craig A. Speigel, MD
Bridgeton, Missouri, 63044
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599
Coastal Pediatric Research
Charleston, South Carolina, 29414
Colorado Springs Health Partners, HCP-Clinical Research, LLC
Colorado Springs, Colorado, 80922
Kindred Medical Institute for Clinical Trials, LLC
Corona, California, 92879
WCCT Global, LLC
Costa Mesa, California, 92626
Ohio Pediatric Research Association
Dayton, Ohio, 45414
Pediatric Specialists of Virginia
Fairfax, Virginia, 22031
Nova Southeastern University
Fort Lauderdale, Florida, 33314
Cook Children's Medical Center
Fort Worth, Texas, 76104
Homestead Research Institute
Homestead, Florida, 33030
RM Medical Research
Homestead, Florida, 33030
HealthStar Research, LLC
Hot Springs, Arkansas, 71913
Texas Children's Hospital/Baylor College Medicine
Houston, Texas, 77030
Houston Clinical Research Associates
Houston, Texas, 77090
Riley Hospital for Children at Indiana University Health
Indianapolis, Indiana, 46202
GI Associates and Endoscopy Center
Jackson, Mississippi, 39232
Pediatric Care Specialists
Johnstown, Pennsylvania, 15904
Midwest Children Health Research Institute
Lincoln, Nebraska, 68505
Midwest Children Health Research Institute
Lincoln, Nebraska, 68516
Applied Research Center of Arkansas
Little Rock, Arkansas, 72212
Ark Clinical Research
Long Beach, California, 90806
ACTCA, Inc
Los Angeles, California, 90017
Children's Hospital Los Angeles
Los Angeles, California, 90017
Kosair Children's Hospital - Pediatric Clinical Research Unit
Louisville, Kentucky, 40202
Advanced Medical Research Center
Miami, Florida, 33135
University Of Minnesota
Minneapolis, Minnesota, 55455
Goryeb Children's Hospital
Morristown, New Jersey, 07962
Coastal Pediatrics Associates
Mt. Pleasant, South Carolina, 29464
Columbia University Medical Center and Morgan Stanley
New York, New York, 10032
Michael W. Simon, MD, PSC
Nicholasville, Kentucky, 40356
IPS Research Company
Oklahoma City, Oklahoma, 73103
Orange County Research Institute
Ontario, California, 91762
Center for Clinical Trials, LLC
Paramount, California, 90723
St. Christopher's Hospital for Children
Philadelphia, Pennsylvania, 19134
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania, 15224
Preferred Primary Care Physicians, Inc.
Pittsburgh, Pennsylvania, 15236
Rhode Island Hospital
Providence, Rhode Island, 02903
Capital Pediatrics and Adolescent Center PLLC
Raleigh, North Carolina, 27609
Virginia Tech Carilion School of Medicine Pediatric
Roanoke, Virginia, 24013
Foothill Family Clinic South / J. Lewis Research, Inc.
Salt Lake City, Utah, 84121
Sun Research Institute
San Antonio, Texas, 78215
Southwest Children's Research Associates, P.A.
San Antonio, Texas, 78229
UCSD Rady Children's Hospital
San Diego, California, 92123
University of California at San Francisco
San Francisco, California, 94143
Frontier Clinical Research, LLC
Scottdale, Pennsylvania, 15683
Seattle Children's Hospital
Seattle, Washington, 98105
Willis-Knighton Physician Network
Shreveport, Louisiana, 71118
Montgomery Medical Inc.
Smithfield, Pennsylvania, 15478
SCORE Physician Alliance, LLC
St. Petersburg, Florida, 33710
Sleepcare Clinical Research Institute
Stockbridge, Georgia, 30281
Ventura Clinical Trials
Ventura, California, 93003
ClinPoint Trials
Waxahachie, Texas, 75165
Heartland Research Associates, LLC
Wichita, Kansas, 67205
Canada2 sites
Stollery Children's Hospital
Edmonton, Alberta, T6G 2B7
Children's Hospital of Western Ontario
London, Ontario, N6A 4G5
About this study
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children, Ages 6 to 17 Years, Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)
The purpose of this study was to evaluate dose response of the safety and efficacy of linaclotide for the treatment of functional constipation (FC), in children age 6-17 years. This study includes up to a 4-week Screening Period, and a 2 to 3-week Pretreatment Period. Participants age 6-11 years will receive oral liquid formulation and participants 12-17 years will receive solid oral capsule or liquid oral solution.
Children ages 6-11 years meeting the entry criteria will be randomized to 1 of 3 doses of linaclotide or placebo for 4 weeks. Children ages 12-17 years meeting the entry criteria will be randomized to 1 of 4 doses of linaclotide or placebo for 4 weeks.
This 4-week study will assess the effects of linaclotide on bowel movement frequency, as well as other bowel symptoms of FC.
- Being tested
- Placebo, LIN Dose A, LIN Dose B, LIN Dose C, LIN 145 µg
- Keywords
- Functional constipation in children, LINZESS
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PlaceboDrug
Participants received matching placebo LIN liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
LIN Dose ADrug
Also called LINZESS
Participants received LIN 9 or 18 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
LIN Dose BDrug
Also called LINZESS
Participants received LIN 18 or 36 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
LIN Dose CDrug
Also called LINZESS
Participants received LIN 36 or 72 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
LIN 145 µgDrug
Also called LINZESS
Participants received LIN 145 µg, liquid solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | Participants aged 6 to 11 or 12 to 17 years received matching placebo linaclotide (LIN), 30 minutes before evening meal, once daily for 4 weeks. Administered as liquid oral solution for participants 6 to 11 years of age and solid oral capsule or liquid oral solution for participants 12 to 17 years of age. Receives: Drug: Placebo |
| LIN Dose A (9 ug or 18 ug) | Experimental | Participants aged 6 to 11 years with weight 18 to <35 kg received LIN 9 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 18 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 18 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks. Receives: Drug: LIN Dose A |
| LIN Dose B (18 ug or 36 ug) | Experimental | Participants aged 6 to 11 years with weight 18 to <35 kg received LIN 18 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 36 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 36 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks. Receives: Drug: LIN Dose B |
| LIN Dose C (36 ug or 72 ug) | Experimental | Participants aged 6 to 11 years with weight 18 to <35 kg received LIN 36 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 72 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 72 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks. Receives: Drug: LIN Dose C |
| LIN 145 µg | Experimental | Participants aged 12 to 17 years received LIN 145 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks. Receives: Drug: LIN 145 µg |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline (CFB) in 4-week Overall Spontaneous Bowel Movement (SBM) Frequency Rate During the Treatment Period
SBM was defined as a BM that occurred in the absence of laxative, suppository, or enema use on the calendar day of the BM or the calendar day before the BM. SBM rate was defined as SBMs/week during the 4-week Treatment period. Participants recorded the occurrence of BMs and use of rescue medication, morning and evening, daily in an eDiary since pretreatment period. The SBM frequency rate (SBMs/week) during the analysis period for each participant were calculated as [(total number of SBMs in the analysis period/number of days in the analysis period)*7]. Baseline value was based on values collected 14 days before randomization up to randomization. Change from Baseline was calculated as the SBM frequency rate during the 4-week treatment period - SBM frequency rate at baseline. A positive change from Baseline indicates improvement. Least squares mean (LSM) and standard error (SE) were calculated using analysis of covariance (ANCOVA) method.
Measured: Baseline (14-day prior to randomization and up to randomization) to Week 4
Secondary outcomes (6)
Change From Baseline (CFB) in 4-week Daytime Abdominal Pain
The abdominal pain score was measured using 5-point scale. Participants answered the questions, How much did your tummy hurt as: 0=none, 1=a tiny bit, 2=a little, 3=some, and 4=a lot. The 4-week daytime abdominal pain was calculated as the average of nonmissing scores in evening eDiary during the Treatment Period with higher value indicating greater symptom severity. Baseline value was the average of non-missing values collected 14 days before randomization. Change from Baseline was calculated as the daytime abdominal pain score during the 4-week treatment period (i.e. average of non-missing daytime scores during 4-week treatment period) - daytime abdominal pain score at baseline. A negative change from Baseline indicates improvement. LSM and SE were calculated using ANCOVA method.
Measured: Baseline (14-day prior to randomization) to Week 4
Change From Baseline (CFB) in 4-week Stool Consistency
Participants used 7-point pediatric Bristol Stool Form (p-BSFS) scale to rate stool consistency for each BM in morning and evening eDiary where 1=small hard lumps or balls like pebbles,2=fat sausage shape but lumpy and hard,3=a sausage but with cracks on it,4=sausage or snake, smooth and soft,5=chicken nuggets, soft smooth blobs,6=oatmeal, fluffy mushy pieces,7=milkshake, watery. Scores in 4-week treatment period were calculated by 2 approaches-1) following derivation similar in earlier adult studies, mean of participants non-missing, SBM associated p-BSFS scores during 4-week treatment period (adult derivation),2) observed weighted average of daily p-BSFS scores during that period. Daily p-BSFS score was average of non-missing morning and/or evening assessments of p-BSFS score from SBMs reported by participants on that specific day. Baseline value was based on values collected 14 days before randomization up to randomization. LSM and SE were calculated using ANCOVA method.
Measured: Baseline (14-day prior to randomization and up to randomization) to Week 4
Change From Baseline (CFB) in 4-week of Severity of Straining
Severity of straining was scored on 5-point scale for question-When you pooped, how hard did you push? The score ranges from 0= not hard at all,1= I pushed a tiny bit hard,2= I pushed a little hard,3= I pushed hard,4= I pushed very hard with higher scores indicating more severe straining. Participants recorded degree of straining for each BM in morning and evening eDiary. Data was derived as adult derivation and weighted average. Scores during 4-week treatment period were calculated following two approaches - (1) following derivation similar in earlier adult studies, as mean of participant's non-missing, SBM associated straining scores during 4-week treatment period (adult derivation) and (2) as observed weighted average of daily straining scores during that period. Daily straining score was the average of non-missing morning and/or evening assessments of straining score from the SBMs reported by the participants on that specific day. LSM and SE were calculated using ANCOVA method.
Measured: Baseline (14-day prior to randomization and up to randomization) to Week 4
Change From Baseline (CFB) in 4-week Abdominal Bloating Daytime Symptoms Based on Evening Assessment
Participants recorded their assessment of abdominal bloating in the evening eDiary. Participants answered the question: How big and full did your tummy feel? on a scale, where: 0=none, 1=a tiny bit, 2=a little, 3=medium or 4=very, with a higher score indicating more severe bloating. Baseline value was the average of values collected 14 days before randomization. The 4-week daytime abdominal bloating symptoms were calculated as the average of non-missing scores reported in the evening eDiary during the treatment period. Change from Baseline was calculated as the 4-week daytime abdominal bloating score during the treatment period - daytime abdominal bloating score at baseline. A negative change from Baseline indicates improvement. LSM and SE were calculated using ANCOVA method.
Measured: Baseline (14-day prior to randomization) to Week 4
Change From Baseline (CFB) in 4-week Overall Complete Spontaneous Bowel Movement Frequency Rate (CSBM/Week) During the Treatment Period
SBM was defined as a BM that occurred in the absence of laxative, suppository, or enema use on the calendar day of the BM or the calendar day before the BM. A CSBM was an SBM that was associated with a sense of complete evacuation. Participants recorded their assessment of the sensation of incomplete evacuation for each BM in the morning and evening eDiary. The 4-week overall CSBM frequency rate was calculated as [total number of CSBMs in the analysis period/number of days in the analysis period]*7). Baseline value was based on values collected 14 days before randomization and up to randomization. Change from Baseline was calculated as the CSBM frequency rate during the 4-week treatment period - CSBM frequency rate at baseline. A positive change from Baseline indicates improvement. LSM and SE were calculated using ANCOVA method.
Measured: Baseline (14-day prior to randomization and up to randomization) to Week 4
Change From Baseline in 4-week Fecal Incontinence Daytime Symptoms Based on Evening Assessment
Participants recorded the presence of incontinence episodes in daytime daily since pre-treatment period (14-day prior to randomization) in the evening eDiary for participants randomized following protocol amendment #3. The 4-week daytime fecal incontinence was calculated as the mean of non-missing participant scores reported in the evening eDiary during the Treatment Period. Baseline value was the average of values collected 14 days before randomization. Change from Baseline was calculated as the 4-week fecal incontinence daytime symptoms during the treatment period - fecal incontinence daytime symptoms at baseline. A negative change from Baseline indicates improvement.
No data is reported for LIN 145 μg as it was an exploratory arm group.
Measured: Baseline (14-day prior to randomization) to Week 4
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Sep 2015 (estimated)
- Study start3 Nov 2015
- Primary completion20 Apr 2018
- Study completion29 May 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Functional Constipation in Children Ages 6-17 YearsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 173 participants (actual)
Sponsor and investigators
- Lead sponsor
- Forest Laboratories
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Ironwood Pharmaceuticals, Inc.
- Responsible party
- Sponsor
- Investigators
- Taryn Weissman, Study director, Allergan, LLC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02559570
- Sponsor's protocol ID
- LIN-MD-62
- Status last verified
- Jun 2019
- First submitted
- 23 Sep 2015
- Last updated
- 19 Jun 2019
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Jun 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children, Ages 6 to 17 Years, Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)
- ClinicalTrials.gov ID
- NCT02559570
- Acronym / sponsor ID
- LIN-MD-62
- Keywords
- Functional constipation in children, LINZESS
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 173 participants (actual)
- Lead sponsor
- Forest LaboratoriesIndustry (pharma, biotech, devices)
- Collaborators
- Ironwood Pharmaceuticals, Inc.
- Study start
- 3 Nov 2015 (actual)
- Primary completion
- 20 Apr 2018 (actual)
- Study completion
- 29 May 2018 (actual)
- First posted
- 24 Sep 2015 (estimated)
- Results
- Posted 14 May 2019
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study was to evaluate dose response of the safety and efficacy of linaclotide for the treatment of functional constipation (FC), in children age 6-17 years. This study includes up to a 4-week Screening Period, and a 2 to 3-week Pretreatment Period. Participants age 6-11 years will receive oral liquid formulation and participants 12-17 years will receive solid oral capsule or liquid oral solution.
Children ages 6-11 years meeting the entry criteria will be randomized to 1 of 3 doses of linaclotide or placebo for 4 weeks. Children ages 12-17 years meeting the entry criteria will be randomized to 1 of 4 doses of linaclotide or placebo for 4 weeks.
This 4-week study will assess the effects of linaclotide on bowel movement frequency, as well as other bowel symptoms of FC.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Drug: PlaceboParticipants aged 6 to 11 or 12 to 17 years received matching placebo linaclotide (LIN), 30 minutes before evening meal, once daily for 4 weeks. Administered as liquid oral solution for participants 6 to 11 years of age and solid oral capsule or liquid oral solution for participants 12 to 17 years of age. |
| LIN Dose A (9 ug or 18 ug) | Experimental | Drug: LIN Dose AParticipants aged 6 to 11 years with weight 18 to <35 kg received LIN 9 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 18 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 18 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks. |
| LIN Dose B (18 ug or 36 ug) | Experimental | Drug: LIN Dose BParticipants aged 6 to 11 years with weight 18 to <35 kg received LIN 18 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 36 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 36 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks. |
| LIN Dose C (36 ug or 72 ug) | Experimental | Drug: LIN Dose CParticipants aged 6 to 11 years with weight 18 to <35 kg received LIN 36 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 72 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 72 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks. |
| LIN 145 µg | Experimental | Drug: LIN 145 µgParticipants aged 12 to 17 years received LIN 145 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks. |
Who may qualify
- Ages
- 6 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (10 listed)
- Participant weighs at least 18 kg (kilograms) (39.7 lbs)
- Participant meets modified Rome III criteria for child/adolescent FC: For at least 2 months before the Screening Visit, the participant has had 2 or fewer defecations (with each defecation occurring in the absence of any laxative, suppository, or enema use during the preceding 24 hours) in the toilet per week. In addition, at least once per week, patient meets 1 or more of the following:
- a) History of retentive posturing or excessive volitional stool retention
- b) History of painful or hard bowel movements (BMs)
- c) Presence of a large faecal mass in the rectum
Key exclusion criteria (8 listed)
- Participant meets Rome III criteria for Child/Adolescent irritable bowel syndrome (IBS): At least once per week for at least 2 months before the Screening Visit, the participant has experienced abdominal discomfort (an uncomfortable sensation not described as pain) or pain associated with 2 or more of the following at least 25% of the time:
- 1. Improvement with defecation
- 2. Onset associated with a change in frequency of stool
- 3. Onset associated with a change in form (appearance) of stool
- Participant reports having more than 1 loose, mushy stool (eDiary-recorded stool consistency of 6 on the Pediatric Bristol Stool Form Scale [p-BSFS]) or any watery stool (eDiary-recorded stool consistency of 7 on the p-BSFS) with any SBM that occurred in the absence of laxative use on the calendar day of the BM or the calendar day before the BM during the 14 days before the randomization day and up to the randomization
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PlaceboParticipants received matching placebo LIN liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks. | Drug | Placebo |
| LIN Dose AAlso: LINZESSParticipants received LIN 9 or 18 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks. | Drug | LIN Dose A (9 ug or 18 ug) |
| LIN Dose BAlso: LINZESSParticipants received LIN 18 or 36 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks. | Drug | LIN Dose B (18 ug or 36 ug) |
| LIN Dose CAlso: LINZESSParticipants received LIN 36 or 72 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks. | Drug | LIN Dose C (36 ug or 72 ug) |
| LIN 145 µgAlso: LINZESSParticipants received LIN 145 µg, liquid solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks. | Drug | LIN 145 µg |
Primary outcome
Change From Baseline (CFB) in 4-week Overall Spontaneous Bowel Movement (SBM) Frequency Rate During the Treatment Period
Time frame: Baseline (14-day prior to randomization and up to randomization) to Week 4
SBM was defined as a BM that occurred in the absence of laxative, suppository, or enema use on the calendar day of the BM or the calendar day before the BM. SBM rate was defined as SBMs/week during the 4-week Treatment period. Participants recorded the occurrence of BMs and use of rescue medication, morning and evening, daily in an eDiary since pretreatment period. The SBM frequency rate (SBMs/week) during the analysis period for each participant were calculated as [(total number of SBMs in the analysis period/number of days in the analysis period)*7]. Baseline value was based on values collected 14 days before randomization up to randomization. Change from Baseline was calculated as the SBM frequency rate during the 4-week treatment period - SBM frequency rate at baseline. A positive change from Baseline indicates improvement. Least squares mean (LSM) and standard error (SE) were calculated using analysis of covariance (ANCOVA) method.
6 secondary outcomes
Change From Baseline (CFB) in 4-week Daytime Abdominal Pain
Time frame: Baseline (14-day prior to randomization) to Week 4
Change From Baseline (CFB) in 4-week Stool Consistency
Time frame: Baseline (14-day prior to randomization and up to randomization) to Week 4
Change From Baseline (CFB) in 4-week of Severity of Straining
Time frame: Baseline (14-day prior to randomization and up to randomization) to Week 4
Change From Baseline (CFB) in 4-week Abdominal Bloating Daytime Symptoms Based on Evening Assessment
Time frame: Baseline (14-day prior to randomization) to Week 4
Change From Baseline (CFB) in 4-week Overall Complete Spontaneous Bowel Movement Frequency Rate (CSBM/Week) During the Treatment Period
Time frame: Baseline (14-day prior to randomization and up to randomization) to Week 4
Change From Baseline in 4-week Fecal Incontinence Daytime Symptoms Based on Evening Assessment
Time frame: Baseline (14-day prior to randomization) to Week 4
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Jun 2019.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Taryn Weissman study director
Allergan, LLC
62 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing LIN Dose A, LIN Dose B and LIN Dose C in people with Functional Constipation in Children Ages 6-17 Years, run by Forest Laboratories at 62 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Jun 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 62 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 14 May 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline (CFB) in 4-week Overall Spontaneous Bowel Movement (SBM) Frequency Rate During the Treatment Period (time frame: Baseline (14-day prior to randomization and up to randomization) to Week 4). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Jun 2019.